Avacta Group Plc (AVCT.L)
| Previous close | 43.20 |
| Open | 42.51 |
| Bid | 42.00 x 0 |
| Ask | 42.50 x 0 |
| Day's range | 42.06 - 43.00 |
| 52-week range | 42.00 - 166.98 |
| Volume | |
| Avg. volume | 3,695,693 |
| Market cap | 151.695M |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 74.67 |
Fool.co.ukDown 63% in 2024, what’s going on with the Avacta (AVCT) share price?
2024 has been a difficult year for many companies in the biotechnology sector, with the AVCT share price down heavily. But is there potential here? The post Down 63% in 2024, what’s going on with the Avacta (AVCT) share price? appeared first on The Motley Fool UK.
Simply Wall St.Avacta Group (LON:AVCT) investors are sitting on a loss of 82% if they invested three years ago
As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So spare a...
Globe NewswireAvacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
5 April 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the American Association of Cancer Research (“AACR”) Annual Meeting in San Diego, California on Tuesday 9 April has now been released by AACR. The poster presentation will
